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The herpes simplex virus (HSV) transactivator VP16 is a structural component of the virion that activates immediate-early
viral gene expression. The HSV-1 mutant in1814, which contains a 12-bp insertion that compromises the transcriptional
function of VP16, replicated to a low level if at all in the trigeminal ganglia of mice (I. Steiner, J. G. Spivack, S. L. Deshmane,
C. I. Ace, C. M. Preston, and N. W. Fraser (1990). J. Virol. 64, 1630–1638; Valyi-Nagy et al., unpublished data). However, in1814
did establish a latent infection in the ganglia after corneal inoculation from which it could be reactivated. In this study, several
HSV-1 strains were constructed with deletions in the VP16 transcriptional activation domain. These viruses were viable in cell
culture, although some were significantly reduced in their ability to initiate infection. A deletion mutant completely lacking the
activation domain of VP16 (RP5) was unable to replicate to any detectable level or to efficiently establish latent infections in
the peripheral and central nervous systems of immunocompetent mice. However, similar to in1814, RP5 formed a slowly
progressing persistent infection in immunocompromised nude mice. Thus RP5 is severely neuroattenuated in the murine
model of HSV infection. However, the activation domain of VP16 is not essential for replication in the nervous system, since
we observed a slow progressive infection persisting in the absence of an immune response. © 1999 Academic Press
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aINTRODUCTION
The nervous system plays a central role in the patho-
enesis of herpes simplex virus (HSV) infections. Both
erotypes of the virus, HSV-1 (the oral form) and HSV-2
the genital form) are capable of life-long persistence
ithin sensory peripheral ganglia in a nonreplicative
atent state. In response to environmental or cellular
hanges, both serotypes can reactivate to produce re-
urrent epithelial eruptions and virus shedding. In addi-
ion, the central nervous system is a major target for
SV-related morbidity and mortality resulting from en-
ephalitis (for reviews, see Hill, 1985; Fraser et al., 1991;
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20raser and Valyi-Nagy, 1993; Whitley and Gnann, 1993;
hitley and Lakeman, 1995).
HSV infects the human host through the epithelium
hat lines the skin or mucous membranes. This initial
nfection results in a regulated cascade of viral gene
xpression, beginning with activation of viral immediate-
arly (IE or a) genes, the products of which in turn
ctivate the early (E or b) genes. Many E gene products
re involved in viral DNA replication, which is followed by
igh level expression of the late (L or g) genes (Roizman
nd Sears, 1996).
VP16 (also known as a-TIF, ICP25, and Vmw65), a
90-amino-acid phosphoprotein component of the virion
egument (Batterson and Roizman, 1983), activates tran-
cription of the immediate-early genes (reviewed in Ward
nd Roizman, 1994; Roizman and Sears, 1996). VP16
ediates transinduction through specific promoter ele-
ents containing TAATGARAT (R 5 purine) and GCG-
AA sequences (Mackem and Roizman, 1982; Gaffney et
l., 1985; Triezenberg et al., 1988b). VP16 does not bind
irectly to either of these conserved motifs, although it
akes minimal contact with the DNA (Marsden et al.,
987; Stern and Herr, 1991). At the TAATGARAT elements,
domain of VP16 located between amino acids 1–400orms a multicomponent DNA-binding complex with the
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21NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1ellular protein Oct-1 as the major determinant of DNA
inding (O’Hare and Goding, 1988; Preston et al., 1988;
ruijn et al., 1988; Kristie et al., 1989; Stern et al., 1989)
nd with HCF (also called VCAF-1 and C1), which facil-
tates the interaction between VP16 and DNA-bound
ct-1 (Katan et al., 1990; Xiao and Capone, 1990; Kristie
nd Sharp, 1993; Wilson et al., 1993). VP16 contributes to
his complex a potent transcriptional activation domain,
ocated between amino acids 410 and 490, that interacts
ith targets within the basal transcription machinery
Cousens et al., 1989; Triezenberg et al., 1988a; Triezen-
erg, 1995). The second promoter element, comprising
he GCGGAA motif, binds a heterodimeric protein known
s GABP (LaMarco et al., 1991; Thompson et al., 1991) or
RF-2 (Virbasius et al., 1993), but no physical association
f VP16 with this DNA-binding protein has been reported.
n addition to its transcriptional activation function, VP16
nteracts with the virion-associated virion host shutoff
rotein (vhs) and restrains its function (Smibert et al.,
994; Lam et al., 1996; Schmelter et al., 1996).
Several studies have explored the properties of HSV
ariants bearing mutations in VP16. The HSV-1 variant
MA (derived from HSV-1 KOS) is a VP16-null mutant that
equires propagation on cells that provide VP16 in trans
Weinheimer et al., 1992). An HSV-2 strain (ts13) report-
dly bears a mutation in the HSV-2 VP16 gene that
enders the virion thermolabile in vitro but had no effect
n IE gene activation (Moss, 1989). Other temperature-
ensitive mutations in VP16 were constructed by replac-
ng certain Cys residues with Gly residues (Poon and
oizman, 1995). The temperature-sensitive effect on vi-
uses expressing these VP16 genes was traced to events
ate in the replicative cycle and not to the IE stage,
espite the fact that the mutant VP16 proteins were
efective in forming complexes with HCF and Oct-1 at IE
romoters. The replication-competent mutant in1814 (de-
ived from HSV-1 strain 171), which contains a 4-amino-
cid insertion at codon 397 of VP16, produces a VP16
rotein that is incorporated into mature virions but lacks
ransinducing activity (Ace et al., 1989). No detectable
eplication of strain in1814 occurred in the trigeminal
anglia (TG) of mice after corneal inoculation (Steiner et
l., 1990). However, subsequent and more sensitive ex-
eriments detected a low level of replication at early
imes postinfection (Valyi-Nagy et al., unpublished obser-
ations). Nevertheless, in1814 established a reactivation-
ompetent latent infection in the TG (Steiner et al., 1990;
alyi-Nagy et al., 1991a). Truncation of the VP16 gene at
odon 422 (deleting most of the transcriptional activation
omain) resulted in a virus with reduced infectivity in
ultured cells (Lam et al., 1996) and reduced IE gene
ctivation, both of which could be compensated by the
resence of hexamethylene bisacetamide, properties
hared with in1814 (Smiley and Duncan, 1997). The prop-
rties of this virus in in vivo infections using an animal
odel system have not yet been described. aIn this study, we investigated the in vitro and in vivo
roperties of HSV-1 mutants with deletions of various
ortions of the activation domain of VP16. These viruses
ere all capable of replicating in tissue culture cells,
lthough infectivity was significantly reduced when the
ctivation domain was deleted (strain RP5). RP5 failed to
ctivate either transfected IE reporter genes or the IE
enes in the viral genome. In contrast to in1814, RP5 was
nable to establish a latent infection in neuronal cells
ollowing corneal inoculation of immunocompetent mice.
urthermore, the ability of RP5 to cause clinical disease
nd to establish latency after intracranial inoculation in
mmunocompetent mice was markedly reduced com-
ared with in1814. These data support the hypothesis
hat the insertion in in1814 does not completely destroy
he transactivation function and that the transcriptional
ctivation domain in VP16 is a neurovirulence determi-
ant.
RESULTS
onstruction of HSV strains bearing deletions of the
P16 activation domain
Previous reports have described an HSV-1 strain
ermed in1814 bearing a four-codon insertion in the VP16
ene (Ace et al., 1989; Steiner et al., 1990; Valyi-Nagy et
l., 1991b). This insertion at codon 397 abolished the
bility of VP16 to trans-activate reporter plasmids with IE
ene promoters, apparently by disrupting the association
f VP16 with the cellular transcription factor Oct-1
hrough which VP16 is tethered to IE promoters. This
irus strain was viable in cell culture but infected cells
nefficiently at low multiplicities of infection (Ace et al.,
989). This virus also showed reduced virulence in mice
Steiner et al., 1990; Valyi-Nagy et al., 1991b). Although no
eplication of this virus was detected in murine TG after
orneal inoculation, the virus did establish and reactivate
rom latency as efficiently as wild-type viruses (Steiner et
l., 1990).
Because the attenuated phenotype of in1814 was most
pparent only at low m.o.i.s, we wished to determine
hether its properties in vivo (ability to replicate at the
eriphery, ability to establish latent infections) might be
ue to partial activity of the transcriptional activation
omain, which remained intact despite the observed
efects in IE gene activation. Therefore we constructed
y homologous recombination a set of viral mutants in
hich the activation domain of VP16 (residues 413–490)
as either partially or entirely deleted (Fig. 1A). RP1 is a
ontrol strain bearing an additional BamHI restriction
ite and a short oligonucleotide segment bearing stop
odons in all reading frames, located 19 bp downstream
f the natural stop codon for the VP16 open reading
rame. The strain designated RP3 is truncated at codon
56 and thus lacks the second subregion of the VP16
ctivation domain termed H2 (Walker et al., 1993) or
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22 TAL-SINGER ET AL.P16C (Sullivan et al., 1998). Strain RP4 lacks the first
ubregion of the activation domain (H1 or VP16N), cor-
esponding to amino acids 413–452. Strain RP5 lacks the
ntire activation region (residues 413–490). For each of
he deletion mutants, rescued viruses were also con-
tructed using a corresponding fragment from the wild-
ype KOS strain. Southern blots of virion DNA clearly
emonstrate the identities of each of the mutant and
escued strains (Figs. 1B and 1C). Immunoblot analysis
f virion proteins, developed using an antibody directed
gainst VP16, revealed that for each virus strain the
orresponding protein is incorporated into virions at ap-
roximately wild-type levels (Fig. 1D). Notably, RP5 is
iable in noncomplementing Vero cells, with efficient
FIG. 1. Virus strains used in this study. (A) Schematic representation o
epeats denoted as blank boxes. In HSV-1 strain 8MA the VP16 gene has
train RP1 is a wild-type revertant of 8MA bearing a BamHI site located
56–490 of the VP16 gene, RP4 lacks codons 413–452, and RP5 lac
ntranslated sequence. The wild-type fragment from the HSV-1 KOS ge
lot of virion DNAs from wild-type and recombinant HSV strains. DNA e
amHI, electrophoresed in agarose gels, blotted to nitrocellulose, a
olecular weight markers. (C) Southern blot of virion DNAs from mutan
resent in mutant virions. Equivalent numbers of virions (;1 3 108) we
itrocellulose, and probed with a rabbit serum (C8–5; Triezenberg et al.,
train RP5 grown in the cell line 16–8, which expressed wild-type V
roportional signals in immunoblots (data not shown).roduction of virions using standard protocols for prep- aration of virus stocks (Fig. 1D and Table 1). When this
train was grown in 16–8 cells, which express a stably
ransformed VP16 gene, the resultant virions bore both
runcated and full-length VP16 at roughly a 2:1 ratio (Fig.
D, RP5/16–8).
The deletions in the VP16 activation domain affected
irus infectivity but not the eventual yield of virions from
onolayers of infected cells (Table 1). The RP3 virus,
hich lacks the C-terminal activation subregion, was not
bviously affected in its in vitro growth properties com-
ared with the wild-type counterpart RP1. RP4 showed a
odest reduction in infectivity, with ratio of particles to
laque-forming units (PFU) approximately 40 times
igher than the wild-type virus. RP5, lacking the VP16
genome. The unique regions (UL and US) are each flanked by inverted
eplaced by the E. coli lacZ gene regulated by the HSV-1 ICP6 promoter.
downstream of the VP16 gene. Strain RP3 bears a deletion of codons
ons 413–490 of the VP16 gene. RP3 and RP5 also lack 19 bp of 39
used to rescue RP3, RP4, and RP5, is shown at bottom. (B) Southern
d from equivalent numbers of virions for each strain was digested with
ridized with a radiolabeled probe from the VP16 gene. M indicates
escued viruses, performed as for (B). (D) Immunoblot of VP16 proteins
and electrophoresed in denaturing acrylamide gels, electroblotted to
directed against purified virion VP16 protein. RP5/16–8 designates viral
tein. In control experiments, serial dilutions of virion samples gavef HSV-1
been r
19 bp
ks cod
nome,
xtracte
nd hyb
t and r
re lysed
1988a)
P16 proctivation domain altogether, was more seriously debil-
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23NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1tated, yielding virus stocks whoseinfectivity was re-
uced by more than two orders of magnitude. This deficit
as more pronounced at lower m.o.i.s, asrevealed by the
rowth curves shown in Fig. 2A. The defects in infectivity
hown by RP4 and RP5 were not overcome by the VP16
rotein expressed in the complementing cell line 16–8;
TABLE 1
Titers and Virion Concentrations of Recombinant
Viral Strains Grown in Vero Cellsa
Virus Titer (PFU/ml) Virions per ml Virion/PFU ratio
P1 3.9 3 108 3.4 3 109 8.6
P3 5.8 3 108 5.3 3 109 9.1
P4 3.3 3 107 1.2 3 1010 360
P5 3.1 3 106 3.6 3 109 1200
P4R 1.1 3 109 6.1 3 109 5.5
P5R 1.1 3 109 6.3 3 109 5.7
a Viral strains were titered on Vero cells by plaque assays. Virions
ere counted by electron microscopy using latex bead concentration
tandards. Results reflect triplicate assays of a single representative
tock of each virus.
FIG. 2. Infectivity of HSV-1 strains bearing deletions in the VP16 activa
ymbols), RP5 (squares), and RP5 grown in 16–8 cells (circles). Vero c
er cell for RP1 and RP5/16–8, 1 PFU per cell for RP5) or low multiplic
nfection, cells and supernatants were harvested, cells were lysed by so
n Vero cells. (B) Stocks of the recombinant viruses RP1, RP3, RP4, and
arvesting virus after extensive cytopathic effect was evident. The titers
ell line 16–8 by plaque assay. (C) Viral DNAs present in preparations of
ere isolated and DNA was extracted. Southern blot hybridizations were periters of virus stocks produced in Vero cells were the
ame when assayed on 16–8 cells as on Vero cells (Fig.
B). This result implies that the virion-borne VP16 must
ave properties important for infection that the stably
ntegrated VP16 gene cannot provide. However, when
he RP4 and RP5 strains were grown in 16–8 cells, the
esulting viruses had high titers indistinguishable from
hose of wild-type virus (data not shown). The defects in
nfectivity of RP4and RP5 cannot be attributed to binding,
ntry, or nuclear localization of the viral genome because
outhern blots of DNA isolated from nuclei of infected
ells showed equivalent amounts of viral DNA when
quivalent particle numbers were used to initiate the
nfection (Fig. 2C). Despite the differences in infectivity,
hen monolayers were allowed toproceed to full cyto-
athic effect (which took considerably longer for the RP4
nd RP5 viruses), the numbers of virions produced by
P4 and RP5 were equivalent to the numbers produced
rom wild-type viruses (Table 1), and the amounts of viral
NA and of VP16 protein contained in those virions were
lso approximately equivalent (Figs. 1B and 1D). These
bservations suggest that the RP4 and RP5 viruses have
main. (A) Growth curves of HSV-1 strains RP1 (represented by diamond
re infected at either high multiplicity (solid symbols and lines; 10 PFU
n symbols and broken lines; 0.1 PFU per cell). At various times after
n, and the titer of virus in the extract was determined by plaque assays
ere prepared by infecting Vero cell monolayers at low multiplicity and
se stocks were assessed on both Vero cells and the VP16-expressing
r DNA from infected cells. Four hours after infection of Vero cells, nucleition do
ells we
ity (ope
nicatio
RP5 w
of the
nuclea
formed as in Fig. 1.
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24 TAL-SINGER ET AL.o significant deficit in virion formation or packaging of
iral DNA.
ranscriptional activation by VP16 mutant viruses
An obvious hypothesis is that the defects in infectivity
esult from reduced transcriptional activation of IE genes
y the mutant VP16 proteins. To assess how well these
iruses can activate IE gene promoters, plasmids ex-
ressing the CAT reporter gene under control of each of
he IE promoters were transfected into mouse L cells.
hese cells were then infected with equivalent numbers
f virions of each recombinant virus. Figure 3 shows that
ach of the various reporter plasmids responded to VP16
ctivation by the wild-type virus with effects ranging from
.5-fold activation (ICP22-CAT) to 160-fold (ICP27-CAT).
runcation of VP16 at residue 456 (RP3) had little or no
ffect on transcriptional activation, except on the ICP27-
AT reporter where activation fell from 160- to 60-fold.
owever, neither RP4 nor RP5 effectively activated any of
he IE-CAT reporter genes. These results were confirmed
sing a different reporter gene system, in which the ICP0
nd ICP4 promoters were linked to the thymidine kinase
ene. Primer extension assays (Fig. 3E) demonstrated
hat RP1 and RP3 effectively activated expression from
oth promoters. In contrast, neither RP4 nor RP5 acti-
ated expression from either reporter gene, although the
P5R rescued strain and the RP5 virus grown in the
omplementing cell line 16–8 activated expression as
ffectively as the wild-type viruses.
The failure of RP4 to activate transfected reporter plas-
FIG. 3. Activation of transfected reporter genes by recombinant vir
ransfected with reporter gene plasmids expressing the bacterial ch
romoter (A), the ICP4 promoter (B), the ICP22 promoter (C), or the ICP
he recombinant virus strains shown in the presence of cycloheximide
emoved and actinomycin D was added to permit the translation of ex
xtracts were prepared and assayed for CAT enzymatic activity by the
ransfected and infected cell cultures. Primer extension experiments (E)
ene plasmids expressing the HSV thymidine kinase gene under the co
ong terminal repeat. Forty hours after transfection, cells were infected w
otal cell RNA was isolated and assayed by primer extension using a p
roducts corresponding to transcripts from each of the reporter plasmids was surprising given that the RP4 virus grows eeasonably well in culture and the transcriptional activa-
ion subregion present on the RP4 VP16 protein can
unction in similar transfection experiments when fused
o the Gal4 DNA binding domain (Sullivan et al., 1998). To
ssess the ability of RP4 and the other recombinant
iruses to activate the IE promoters in the context of the
irus itself, we assayed viral IE gene expression by
everse transcription followed by polymerase chain re-
ction amplification (RT–PCR). At various times after in-
ection, total RNA was harvested from infected cells.
fter reverse transcription using oligo-dT as primer, PCR
eactions were performed using sets of primers specific
o each IE gene. As an internal control for effective PCR
mplification, a set of primers specific for the cellular
yclophilin gene were included in each reaction. Figure
shows the results for a single representative time point
4 h p.i.) where it appears that RP1, RP3, and RP4 all
ctivated expression from each of the viral IE promoters,
hereas RP5 activated expression of these genes
eakly if at all.
P5 does not replicate efficiently in murine eyes
The in vitro infection properties of RP5 are similar in
everal respects to the properties of strain in1814 (Ace et
l., 1989). However, the following experiments demon-
trate that the in vivo properties of RP5 differ from those
f in1814 with respect to virulence and latency in infected
ice.
Replication of virus in infected eyes was examined
fter corneal inoculation of BALB/c mice with 105 PFU/
1
earing deletions in the VP16 activation domain. Mouse L cells were
henicol acetyltransferase (CAT) gene under the control of the ICP0
oter (D). Forty hours after transfection, cells were infected by each of
nt synthesis of viral IE proteins. Three hours later, cycloheximide was
d mRNAs without allowing further transcription. Two hours later, cell
ffusion method. Bars represent means of at least three independently
lso performed by simultaneously transfecting L cells with three reporter
the ICP0 promoter, the ICP4 promoter, and the Moloney sarcoma virus
recombinant virus strains in the presence of cycloheximide. After 2 h,
pecific to the tk gene transcript. The positions of the primer extension
indicated at the right.uses b
loramp
27 prom
to preve
presse
fluor-di
were a
ntrol of
ith the
rimer sye of wild-type viruses (RP1, 17 , or the rescued virus
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25NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1P5R), or the mutant viruses (RP5 or in1814). As ex-
ected, increasing titers of infectious virus were de-
ected in eye homogenates up to 96 h after infection with
he wild-type viruses (Fig. 5A). In contrast, no infectious
irus was detected in RP5-infected eyes after 24 h p.i.
imilar to previous observations (Steiner et al., 1990),
n1814 titers at all time points were three orders of mag-
itude lower than those of wild-type viruses. To ensure
hat viral titers obtained were not due to inoculum, early
ime points were also analyzed. At 12 h p.i., no infectious
irus was detected in homogenates of eyes infected with
P5 or in1814, suggesting that the virus obtained after
4 h was the product of viral replication. Thus RP5
eplicates poorly in mouse eyes and shows less replica-
ion than the VP16 mutant in1814.
P5 does not replicate in TG from immunocompetent
ice
Viral replication in trigeminal ganglia of mice after
orneal inoculation was also assessed (Fig. 5B). Al-
hough wild-type viruses showed increasing viral titers in
G homogenates, no infectious virus was detected in TG
omogenates from mice infected with either RP5 or
n1814. This observation is consistent with our previous
eport indicating lack of replication of in1814 in TG. Al-
FIG. 4. Expression of viral IE genes in infection by recombinant HSV
trains bearing deletions in the VP16 activation domain. Vero cells were
nfected with the indicated HSV-1 strains. At various times after infec-
ion, total cell RNA was harvested; this figure shows duplicate samples
rom 4 h p.i. After synthesis of cDNA by reverse transcriptase, PCR
eactions were performed with primer sets specific to the ICP0, ICP4,
CP22, or ICP27 genes. PCR products were electrophoresed in 4%
uSieve agarose gels and stained with ethidium bromide. The posi-
ions of the IE-specific RT-PCR products are indicated by arrows on left.
he positions of PCR products from a primer set specific to the endog-
nous cyclophilin gene, included in each reaction as an internal con-
rol, are indicated by arrows on right.hough no differences between the two VP16 mutant giruses can be distinguished in the assay, the results
learly point to an inability of the RP5 mutant to replicate
n neuronal tissues.
P5 does not establish latent infection in murine TG
We previously reported that in1814 establishes latent
nfection in murine TG as determined by the presence of
eactivation-competent virus (Steiner et al., 1990) and by
he presence of the latency-associated transcript (LAT) in
he TG at 4 weeks after infection (Valyi-Nagy et al., 1992).
n this study, multiple LAT-positive neurons were ob-
erved by in situ hybridization in BALB/c mice infected
ith RP1 (Fig. 6A). In contrast, no LAT expression was
etected in TG of RP5-infected animals (Fig. 6B). More-
ver, in explant cocultivation experiments, 100% of RP1-
nfected ganglia reactivated by 13 days postexplantation,
ut no infectious virus was detected in TG explants
btained from RP5-infected animals (Fig. 7). Thus RP5 is
ifferent from in1814 in its reduced ability to establish
eactivatable latent infection in murine TG after corneal
noculation.
P5 infection is severely attenuated in the CNS
The inability to detect latent virus in the TG of
P5-infected mice may be due to limited viral replica-
ion in eyes (Leib et al., 1989; Steiner et al., 1990). To
ddress this question, BALB/c mice were inoculated
ntracranially as described under Materials and Meth-
ds with 105 PFU of RP1, RP5R, or RP5 (grown on Vero
ells). RP1- and RP5R-infected mice (5/5 and 3/3, re-
pectively) died within the first 4 days after infection
Table 2). HSV-1 gene expression was detected in
ultiple brain regions, as determined by immunostain-
ng using a polyclonal antibody specific to HSV (Fig.
FIG. 5. Viral titers in BALB/c eyes and TG during acute infection with
P1, RP5R, in1814, and RP5. Each point represents the geometric mean
iter determined from six individual eye or trigeminal ganglia homoge-
ates at the indicated time (hours) postinfection. Virus titrations were
one on 16–8 cell monolayers in duplicate. (A) Eyes. (B) Trigeminal
anglia.
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26 TAL-SINGER ET AL.C) and in situ hybridization for LAT (Fig. 6D). These
esults indicate that mortality was induced by viral
ncephalitis. In contrast to these wild-type viruses, the
P16 mutant virus RP5 was nonlethal, and all five mice
urvived the infection without demonstrating signs of
llness (ruffled furs, arched backs, weight loss). In
ice sacrificed at 4 days after inoculation, RP5 gene
xpression was detected primarily in ependymal cells
n the epithelial lining of the ventricles (Figs. 6E and
FIG. 6. Detection of HSV-1 gene expression in infected tissues by immun
ith RP1 (A) or RP5 (B) via the corneal route. At 40 days postinfection, trig
xpression. (C–H) BALB/c mice were infected intracranially with RP1 (C a
hat died 3 days after infection were analyzed by immunostaining (C) or I
nalyzed by immunostaining for HSV-1 antigen (E and F). Antigen-positive
nfection with RP5, mice were sacrificed and brain sections were analyzed b
ell in the subependymal region (H). Magnification 5 3400 (A, B, and H)F). Antigen expression was also detected in a few hortical neurons (Fig. 6F). Moreover, brain ventricles
ere enlarged (Figs. 6E and 6F), possibly due to the
bstruction of flow of the cerebrospinal fluid due to
loughing of the infected ependymal cells layer. By
ay 40, the ependymal layer was destroyed and the
entricles remained enlarged (Fig. 6G). At Day 40,
here was no detectable viral antigen expression by
mmunostaining (not shown), indicating the lack of
cute RP5 replication. LAT was detected by in situ
g and in situ hybridization for LAT. (A and B) BALB/c mice were inoculated
ganglia sections were assayed by in situ hybridization (ISH) for LAT RNA
r RP5 (E–H). Sections prepared from the brain of an RP1-infected animal
for viral gene expression. At 4 days postinfection with RP5, brains were
the ependyma are denoted as (e). (G and H) At 40 days after intracranial
The ventricle is denoted as (v) (G); the arrow denotes a single LAT-positive
(D–G), and 3100 (C).ostainin
eminal
nd D) o
SH (D)
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27NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1ubependymal regions (Fig. 6H). Thus RP5 shows a
educed ability to replicate in the brain and to estab-
ish latency after intracranial inoculation, similar to the
esults obtained with corneal inoculation.
ong-term survival of RP5-treated mice
All RP5-infected BALB/c mice survived longer than 40
ays after infection (Table 2). Similar survival results
ere obtained using 106 PFU of RP5 grown on comple-
enting 16–8 cells (Table 2); these virions carry equal
roportions of wild-type and truncated VP16 protein and
ave wild-type infection properties in tissue culture cells
FIG. 7. Explant-reactivation from TG of latently-infected mice. BALB/c
ice were infected with 105 PFU/eye of RP1 or RP5. At 4 weeks after
nfection, 10 ganglia of RP1 (squares) and 10 ganglia of RP5 (triangles)
ere explanted and cocultivated with monolayers of VP16-comple-
enting 16–8 cells. Reactivation was scored as positive when CPE was
etected. No CPE was observed in RP5 explant cultures. Cultures were
bserved for 40 days.
T
Survival of Mice Aft
Mouse type HSV-1 strain
Infecting titer
PFU
BALB/c RP1 105
RP5 (16-8) 105
RP1 105
RP5 105
RP5R 105
RP1 106
RP5 (16-8) 106
C57Bl/b in1814 106
in1814 105
RP5 (16-8) 105
RP5R 105
Nude RP5 105
Mockd
wt UV-irradiatede
a Mice were inoculated after corneal scarification (Oc) or by intracra
b Percentages in parentheses.
c Surviving mice were observed for $200 days.
d Mock-infected mice were inoculated with 10 microliters of serum-f
e UV-irradiated wild-type virus equivalent to 105 PFU.Figs. 1 and 2). Thus even RP5 viruses capable of a
ingle round of replication are not lethal after intracranial
noculation. Moreover, these results indicate that RP5 is
ore attenuated than in1814, which had an LD50 (mini-
um dose of virus that kills 50% of infected animals) of
.4 3 103 PFU in intracranially inoculated mice (strain
nspecified; Ace et al., 1989). To determine whether RP5
as attenuated in more than one host strain and to
ompare RP5 and in1814 directly, C57Bl/6 mice were
njected intracranially with 105 PFU RP5, in1814, or RP5R.
nimals infected with RP5R and in1814 died within the
irst week after infection. in1814-infected animals died
rom HSV-induced encephalitis, as determined by immu-
ostaining for HSV antigen even at low infecting titers
results not shown). In contrast, only one of five mice
nfected with RP5 died after 10 days (Table 2). Therefore
n1814 is more virulent than RP5.
P5 forms persistent infection in nude mice
We have previously shown (Valyi-Nagy et al., 1992,
994b) that in1814 and a thymidine-kinase (TK)-deficient
SV-1 mutant established both latent and slowly pro-
ressing infections in the TG after corneal inoculation of
ice with severe combined immunodeficiency (SCID)
Bosma et al., 1983). In recent studies (Lasner et al., 1996,
998), we reported that an HSV-1 variant (strain 1716)
earing a deletion in the g34.5 gene causes toxicity in
ude mice; this results from persistent neuronal replica-
ion in multiple brain regions. To determine whether RP5
s virulent in immunocompromised animals, we inocu-
ated 20 nude mice with 105 PFU/brain. During the first 4
ulation with HSV-1
Route of
inoculationa Survival (%)b
Time of death
days post-infectionc
Oc 14/14 (100)
Oc 15/15 (100)
IC 0/5 (0) 3–4
IC 5/5 (100)
IC 0/3 (0) 4
IC 0/5 (0) 3–4
IC 5/5 (100)
IC 0/2 (0) 4
IC 0/5 (0) 4, 5, 6
IC 4/5 (80) 10
IC 0/5 (0) 4
IC 16/20 (80) 26, 31, 40, 46
IC 5/5 (100)
IC 5/5 (100)
ection (IC).
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28 TAL-SINGER ET AL.eeks, none of the mice showed signs of disease. How-
ver, four mice died on Days 26, 28, 40, and 46 after
nfection (Table 2). RP5 replication was detected by im-
unostaining in multiple brain regions (not shown).
hree surviving mice were sacrificed, and two brains
tained positive for HSV antigen. Therefore although RP5
s less virulent than other HSV-1 mutants, it is capable of
stablishing persistent and sometimes lethal infection in
subpopulation of immunocompromised hosts.
DISCUSSION
HSV-1 VP16 is a virion tegument protein that stimu-
ates transcription of IE genes during lytic infection
Batterson and Roizman, 1983; Campbell et al., 1984;
reston et al., 1984). The transcriptional activation do-
ain of VP16, which resides in the C-terminal 80 amino
cids of the protein (Triezenberg et al., 1988a; Cousens
t al., 1989), is an important model for mechanisms of
ranscriptional activation. Most investigations of the
unction of the VP16 activation domain have been in
eterologous biological or in vitro systems. In this study,
e investigated the role of the VP16 activation domain in
he infectious processes of HSV-1 by constructing mu-
ant viruses bearing deletions of some or all of the VP16
ctivation domain. Our results demonstrate the impor-
ance of the VP16 activation domain for lytic infection in
itro and in vivo. Replication of a mutant virus, RP5,
acking the activation domain of VP16 was severely at-
enuated in murine PNS and CNS. RP5 failed to replicate,
fficiently establish latency, or reactivate in murine TG
fter corneal inoculation. Furthermore, RP5 replication
as severely attenuated after intracranial inoculation. In
ontrast to infection with wild-type virus, all immunocom-
etent mice inoculated with RP5 survived infection with-
ut evidence of disease.
Our observations of the in vitro infection properties of
P5 are consistent with those reported for V422, a strain
n which the VP16 gene is truncated at codon 422 (Lam
t al., 1996; Smiley and Duncan, 1997). Both viruses are
pproximately 100-fold less infectious than their wild-
ype parental strain or corresponding rescued strains.
oth viruses fail to activate viral IE gene expression
uring lytic infection in cultured cells. The in vivo infec-
ion properties of V422, however, have not yet been
escribed.
In several respects, the in vitro and in vivo properties
f RP5 also resemble those of HSV-1 mutant in1814 (Ace
t al., 1989), which contains an insertion in its VP16 gene
hat affects the transinducing activity of the gene prod-
ct. However, RP5 differs from in1814 in one significant
spect; whereas in1814 was capable of establishing la-
ency after corneal inoculation, from which virus could be
eactivated by explant cocultivation (Steiner et al., 1990;
alyi-Nagy et al., 1992), the RP5 virus showed no clear
vidence of efficiently establishing or reactivating from batency. Thus these two viruses, both defective in IE viral
rans-activation, show significant differences in latency
nd neuropathogenesis. Some contribution to these phe-
otypic differences may arise from other genetic differ-
nces in the parental strains for RP5 (derived from KOS)
nd in1814 (derived from strain 171) because 171 is more
eurovirulent than KOS. Nonetheless, the phenotypic dif-
erences between RP5 and its KOS parent are more
ronounced than we have previously observed for in1814
nd its parental strain (Steiner et al., 1990; Valyi-Nagy et
l., 1992).
The differences in neuropathogenesis between in1814
nd RP5 may result from either qualitative or subtle
uantitative differences in their abilities to activate viral
E transcription. The mutation in in1814 is a 4-amino-acid
inker insertion at codon 397 (Ace et al., 1989) that dis-
upts the interaction of VP16 with the cellular proteins
ct-1 and HCF but preserves the C-terminal acidic acti-
ation domain. In contrast, the truncated VP16 protein
xpressed from RP5 can effectively form a DNA-binding
omplex with Oct-1 and HCF but lacks the entire tran-
criptional activation domain. Thus the mutant VP16 pro-
ein encoded by in1814 may have a residual transcrip-
ional function which could account for the ability of
n1814 to establish latent infections. This residual func-
ion may also account for the ability of in1814 to activate
E transcription at wild-type levels in high multiplicities of
nfection of cultured cells (Ace et al., 1989).
Alternatively, if both in1814 and RP5 are fully defective
n IE gene activation, then the differences in the neuro-
athogenesis may be due to differences in some other
ctivity of the respective VP16 proteins. One possibility
or this ‘‘other activity’’ is the interaction of VP16 with the
hs protein. Several reports have indicated that VP16
acilitates the persistence of HSV mRNAs in infected
ells at late times by interacting with the viral vhs protein
nd dampening its activity (Smibert et al., 1994; Lam et
l., 1996). The domain of VP16 that interacts with vhs lies
mino-terminal to residue 369 (Smibert et al., 1994),
hereas the transcriptional activation domain resides
ithin 80 amino acids at the C terminus of VP16 (Sad-
wski et al., 1988; Triezenberg et al., 1988a; Cousens et
l., 1989). Therefore the mutation in RP5 should not affect
ts interaction with vhs. This conclusion is supported by
reliminary experiments in which the virion-borne vhs
ctivities of RP1 and RP5 (i.e., at early times during
nfection) were found to be comparable when analyzed
y Northern blots of infected-cell RNA. In contrast, at late
tages of infection (10 h p.i.), the vhs activity in RP5-
nfected cells was markedly reduced (Y. Mao and S.
riezenberg, unpublished results). This difference may
esult from the delay in late gene expression (including
hs expression) in RP5-infected cells that results from
he initial inability to transactivate IE gene expression.
eletion of the vhs gene results in virions that are capa-
le of efficient replication in Vero cells but are unable to
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29NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1stablish acute or reactivation-competent latent infec-
ions in immunocompetent CD-1 mice after corneal in-
culations (Strelow and Leib, 1995). Therefore the re-
uced vhs activity observed at late times in RP5 infection
ay similarly contribute to the severely attenuated phe-
otype of RP5 in vivo. It would be of interest to determine
hether vhs activity is preserved in in1814-infected cells.
Intracranial injection of in1814 into immunocompetent
57Bl/6 mice was lethal at infectious titers as low as 103
FU/brain (Table 2). These results were similar to a
revious observation that the LD50 of in1814 in BALB/c
ice was approximately 7.5 3 103 PFU/brain (Ace et al.,
989). In contrast, RP5 was nonneurovirulent upon intra-
ranial inoculation. BALB/c (100%) and C57Bl/6 (80%)
ice survived infections with as much as 106 PFU/brain
Table 2). Although there was some evidence for infec-
ion of nonneuronal ependymal cells during the acute
tage of infection (Fig. 6F), no symptomatic disease was
bserved. This phenotype resulted from the deletion in
he VP16 gene because RP1 and the rescued virus RP5R
aused lethal encephalitis at those infecting titers (Table
). Moreover, we found no evidence of latent infection in
ALB/c brains after intracranial inoculation. Therefore,
s observed in the PNS, RP5 is profoundly defective in its
bility to establish efficient acute or latent infections in
he CNS of immunocompetent animals. These results
uggest that the transactivation domain in VP16 is im-
ortant for neurovirulence.
In this study we found that RP5 replication was mostly
imited to ependymal cells as previously observed using
ther neuroattenuated HSV-1 mutants such as strains
eficient in ICP34.5 (g34.5) (Thompson et al., 1993; Las-
er et al., 1996). This indicates that ependymal cells are
ighly permissive to HSV infection; however, they are
nable to transmit virus efficiently to the surrounding
ells. It is possible that ependymal cells possess cellular
actors that are strong viral activators capable of com-
ensating for different viral defects.
We have previously found (Valyi-Nagy et al., 1992,
994b) that in1814 and a thymidine-kinase (TK)-deficient
SV-1 mutant established both latent and slowly pro-
ressing infections in the TG after corneal inoculation of
ice with severe combined immunodeficiency (SCID)
Bosma et al., 1983). These infections resulted in occa-
ional deaths (Valyi-Nagy et al., 1992, 1994b). In contrast,
n HSV-1 mutant lacking the g34.5 gene (1716) was
nable to establish persistent infection after corneal or
ntracranial inoculation into SCID mice (Valyi-Nagy et al.,
994a). This mutant formed persistent lethal infections in
subpopulation of nude mice after intracranial inocula-
ion (Lasner et al., 1996, 1997). In this study, we found
vidence for a similar low-level lethal replication in the
rains of nude mice after intracranial inoculation with
P5 (Table 2). These results suggest that in the absence
f mature T cells and an efficient immune response, RP5 ss capable of low-level acute replication in CNS neurons
hat does not require the activity of VP16.
HSV-1 mutants that preferentially replicate in dividing
ells but not in normal postmitotic and/or quiescent brain
ells have been investigated as potential agents for brain
umor therapy (Chambers et al., 1995; Martuza et al.,
991; Markert et al., 1993). We have described the use of
he g34.5 deletion mutant strain 1716 (MacLean et al.,
991) in mouse models of primary human brain tumors
Kesari et al., 1995b; Lasner et al., 1996) and intracranial
elanoma (Randazzo et al., 1995). Because RP5 has a
imilar in vivo phenotype to 1716, we wished to deter-
ine whether RP5 may be useful for brain tumor therapy.
n preliminary experiments, we have determined that
P5 was capable of replication in human neuroblastoma
283 (Friedman et al., 1985) tumor cells and in D283
umors in nude mice (T. M. Lasner, unpublished results).
herefore, RP5 is replication competent in rapidly divid-
ng cells in vivo and, like 1716, may serve as a therapeu-
ic agent. Furthermore, 1716 is capable of efficiently es-
ablishing latent infection in both immunocompetent and
mmunodeficient mice, whereas RP5 does not establish
atency. Therefore RP5 may be a better candidate for
valuation as a tumor therapeutic agent. Studies to de-
ermine whether RP5 kills tumor cells more efficiently
han 1716 are in progress.
MATERIALS AND METHODS
nimals
Female BALB/c BYJ and C57Bl/6 mice (4–6 weeks old)
ere obtained from Jackson Laboratories. Female ho-
ozygous nude mice (4–6 weeks old) were obtained
rom Taconic (Germantown, NY). The animal studies
ere approved by the University of Pennsylvania Institu-
ional Animal Care and Use Committee.
ell cultures
Vero, 16–8, BHK, and L cells were cultured in DMEM
upplemented with either 5 or 10% fetal calf serum (FCS).
irus stocks
HSV-1 strains wild-type 171 (Brown et al., 1973) and
nsertion mutant in1814 (Ace et al., 1989) were grown on
aby hamster kidney 21 clone 13 (BHK) cells. All other
irus strains used in this study are shown in Fig. 1. HSV-1
train 8MA, a gift from S. Weinheimer, was derived from
train KOS by replacing the VP16 gene with the Esche-
ichia coli lacZ gene regulated by the HSV-1 ICP6 pro-
oter (Weinheimer et al., 1992). This strain was propa-
ated in a Vero-derived cell line (designated 16–8) that
xpresses the VP16 gene product (Weinheimer et al.,
992). Strain RP1 was constructed by homologous re-
ombination in Vero cells using viral genomic DNA from
train 8MA and a XhoI–PstI restriction fragment encom-
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30 TAL-SINGER ET AL.assing the VP16 gene. This fragment bore a BamHI site
ocated 19 bp downstream of the VP16 gene followed by
n oligonucleotide with stop codons in all three reading
rames (59-TAGTTAATTGA). Strains RP3, RP4, and RP5
ere constructed similarly using DNA fragments lacking
odons 456–490, 413–452, or 413–490 (respectively) of
he VP16 gene. The mutations in RP3, RP4, and RP5 were
escued by homologous recombination using viral
enomic DNA from the mutant strains and a wild-type
hoI–PstI DNA fragment from strain KOS, yielding vi-
uses designated RP3R, RP4R, and RP5R, respectively.
ecombinant viruses were plaque-purified twice, and
heir identities were confirmed by Southern blot and
mmunoblot analyses. Details of these constructions are
rovided in (Pichyangkura, 1996) and are available upon
equest. Viral stocks were grown and titered on mono-
ayers of Vero cells or in some instances on VP16-
omplementing 16–8 cells (Weinheimer et al., 1992).
ransient tranfection assays
To assess transcriptional activation of IE promoters by
he various VP16 mutant viruses, reporter plasmids were
ransfected into mouse L cells by DEAE-dextran (Lopata
t al., 1984) or into Vero cells by calcium phosphate
oprecipitation. Plasmids expressing the bacterial chlor-
mphenicol acetyltransferase gene under the control of
SV-1 IE promoters were the generous gift of Dr. P. A.
chaffer and Anh Nguyen-Huynh [pAN5, ICP0; pAN6,
CP4; pAN7, ICP22; and pICP27-CAT (Nguyen-Huynh and
chaffer, 1998)]. Forty hours after transfection, cells were
nfected with HSV-1 in the presence of cycloheximide (50
g/ml) to prevent expression of the viral IE gene prod-
cts. After 3 h, medium containing cycloheximide was
eplaced with medium containing actinomycin D (10 mg/
l) to permit translation of the CAT protein from accu-
ulated mRNA. After two additional hours, whole cell
rotein extracts were prepared and assayed for CAT
nzymatic activity using the fluor diffusion method (Neu-
ann et al., 1987; Nielsen et al., 1989).
Plasmids expressing the HSV thymidine kinase gene
nder the control of the ICP4 and Moloney sarcoma virus
romoters have been described (Graves et al., 1985;
riezenberg et al., 1988b). A corresponding ICP0-tk plas-
id was constructed by cloning a PCR-derived promoter
ragment into the same plasmid backbone used for the
CP4-tk reporter gene (P. J. Horn and E. Chung, unpub-
ished). Transfection, subsequent infection, RNA harvest,
nd assay by primer extension were performed as pre-
iously described (Triezenberg et al., 1988b).
iral IE gene expression assays in infected cells
To assess the expression of viral IE genes during
nfection, Vero cells were infected with wild-type or mu-
ant viruses using a number of virions equivalent to 10
FU of RP1 per cell. Total cell RNA was harvested at tarious times after infection using Tri-Reagent (Molecu-
ar Research Center, Inc., Cincinnati OH) followed by
igestion with RNase-free DNaseI (Boehringer). First-
trand cDNA synthesis was primed with oligo-dT and
as extended using Superscript II reverse transcriptase
Gibco BRL). Subsequent PCR reactions included primer
airs specific for the HSV-1 ICP0, ICP4, ICP22, or ICP27
enes (details available upon request). Each reaction
lso included a primer pair specific for the endogenous
yclophilin gene (Tal-Singer et al., 1997). PCR reactions
ere performed using a ‘‘touchdown’’ strategy (Don et al.,
991) in which the hybridization temperature was de-
reased by 1°C after every two cycles, beginning at
0°C. A total of 30 cycles of polymerization (15 temper-
ture steps) was followed by seven additional minutes of
xtension at 72°C. Reaction products were electropho-
esed in 4% NuSieve agarose gels (FMC), stained with
thidium bromide and photographed under UV illumina-
ion.
cular infection of mice
Mice were anesthetized with intraperitoneal injection
f ketamine (87 mg/kg)/xylazine (13 mg/kg) then inocu-
ated after corneal scarification with 105 PFU per eye of
P1, RP5R, RP5 (grown on 16–8 cells), 171, or in1814. At
0 days p.i., some mice were sacrificed by cervical
islocation, and eyes and trigeminal ganglia (TG) were
xcised.
itration of virus from eyes and TG
Other mice were sacrificed 1, 6, 12, 24, 72, or 96 h after
orneal inoculation. Tissues from three mice per time
oint were homogenized in 1 ml serum-free Dulbecco’s
odified Eagle medium (DMEM) using a Pyrex Ten
roek tissue grinder (Bellco Glass, Vineland, NJ). The
omogenates were frozen and thawed once and cleared
y centrifugation at 3000 g for 5 min at 4°C. The super-
atant was diluted logarithmically in media and the viral
iter was determined on 16–8 cells in 48-well plates by
mmunoperoxidase assay (Holland et al., 1983; Hung et
l., 1992; Tal-Singer et al., 1995) using rabbit anti-HSV-1
olyclonal antibody (American Qualex Antibodies, San
lemente, CA). Titers were determined in duplicate
ells.
xplant reactivation
Groups of six explanted TG from latently infected mice
ere cocultivated (Stevens and Cook, 1971) with mono-
ayers of 16–8 cells in DMEM supplemented with 5% fetal
ovine serum at 37°C. Every 6 days, ganglia were trans-
erred to fresh monolayers of 16–8 cells. Reactivation
as considered positive when cytopathic effects were
etected in the cell monolayer within 40 days of cocul-ivation.
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31NEUROPATHOGENICITY OF VP16 ACTIVATION DOMAIN MUTANTS OF HSV-1ntracerebral inoculation
Four- to 6-week-old female BALB/c, nude, or C57Bl/6
ice were anesthetized, and the heads were cleansed
ith 70% ethanol. Following a midline incision, the skull
as perforated using a 25-gauge needle 2 mm caudal of
he bregma and 1 mm left of the midline (Kesari et al.,
995a). The animals were placed in a small-animal ste-
eotactic apparatus (Kopf Instruments, Tujunga, CA), and
n appropriate amount of virus (105–106 PFU of virus in 10
l) or serum-free DMEM (vehicle) was injected using a
0 ml Hamilton syringe with a 27-gauge needle (Kesari et
l., 1996). The injection was performed for 3 min. The
eedle was left in for 3 min after the injection, then
ithdrawn slowly over 1 min, as described previously
Kesari et al., 1995a). The superficial skin wound was
losed with sutures, and the mice were inspected daily
or signs of illness.
mmunostaining procedures
For the studies assessing replication of virus within
he brains, mice were transcardially perfused and fixed
ith 4% paraformaldehyde (0.1 M phosphate-buffered
aline, pH 7.34), and the brains were removed for histo-
ogical and immunohistochemical analysis. Ganglia used
or immunohistochemistry were immersed in 70% etha-
ol/150 mM NaCl for 24 h and then embedded in paraffin
ax. The methods of tissue processing and light micro-
copic immunohistochemical analysis were similar to
hose described elsewhere (Randazzo et al., 1995; Tro-
anowski et al., 1993, 1994). Rabbit polyclonal antisera to
SV-1 (Dako Corp., Carpinteria, CA) was used for detec-
ion of viral antigens as described (Adams et al., 1984;
esari et al., 1995b). Antigen-expressing cells were de-
ected by the indirect avidin-biotin immunoperoxidase
ethod (Vectastain ABC kit, Vector Labs, Burlingame,
A), with 3,39-diaminobenzadine (DAB) as the chroma-
en (Trojanowski et al., 1993). Spread of virus in all
nimals was monitored by screening 4 of 30 sections
6-mm thick) through the brain (5–10 sections apart).
n situ hybridization for HSV-1 specific gene
xpression
In situ hybridization was performed as previously de-
cribed (Deatly et al., 1988). Sections of trigeminal gan-
lia and brain stems from infected mice sacrificed 6
eeks p.i. were mounted on slides. The sections were
ybridized with a latency associated transcript (LAT) spe-
ificnick-translated[35S]-ATP(Amersham)-labeled(BstEII–
stEII) 0.9-kb DNA probe derived from the BamHI B
ragment of the HSV genome (Valyi-Nagy et al., 1992).
fter hybridization, five slides (4–9 sections per slide) for
ach animal were examined. The positive cells in each
ection were counted, and the mean number of positive
ells per section was determined.ACKNOWLEDGMENTS
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